Aspira Women's Health Inc. · OTC:AWHL
Aspira Women's Health — Investor Presentation (November 2020)
42 slides from Aspira Women's Health's investor presentation, November 2020

Slide 1: Multi-Modal Bioinformatics Solution for Ovarian Cancer
“: ASPIRA WOMEN’S EALTH Multi-Modal Biolnformatics Solution for Ovarian Cancer NASDAQ: AWH_ | November 2020

Slide 2: Safe Harbor
SAFE HARBOR This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include, am

Slide 3: Presentation Overview
PRESENTATION OVERVIEW

Slide 4: Our Mission
OUR MISSION Enable Early Ovarian Cancer Detection for All Ages and Ethnicities 4 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved

Slide 5: Investment Highlights
INVESTMENT HIGHLIGHTS 5 Copyright © Aspire Women's Health Inc., 2020. All Rights Reserved. COMMERCIAL STAGE COMPANY FDA-cleared multi-modal disease management approach to women's health, with core focus on ovarian cancer INTELLECTUA PROPERTY Strong intellectual property protecting methods and use FD

Slide 6: Management Team
MANAGEMENT TEAM Leadership team with significant industry and execution expertise KANON tens @labCorp @omenzym Valerie Palmieri President & CEO -¥20+ years of senior and excoutive leaderchip experience inthe ciagnostice and laboratory industry ‘Served in numerous sales, operations and executive lead

Slide 7: Aspira Women's Health's Evolution
ASPIRA WOMEN’S HEALTH’S EVOLUTION ONGOING : Replace Standard of Care & Save Lives OVA1 Plus foundation Ae in place to become — COMPLETED | NEW Sta ndard of Care OVA1 Plus Launch (Q4'18) : Payers (2018-2019) Payer Coverage: 5 out of 10 lives covered Guetinen COSTE inthe U.S. Bioinformatic Tools + Cur

Slide 8: Introduction to Patient Lifecycle and Market
Introduction to Patient Lifecycle and Market “1 ASPI Pes WOMEN'S EALTH 8 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved

Slide 9: Large Market Opportunity with the Following Patient Profiles
LARGE MARKET OPPORTUNITY WITH THE FOLLOWING PATIENT PROFILES HIGH RISK HEREDITARY OVARIAN CANCER MONITORING OVARIAN CANCER 7 Ke 2 PELVIC MASS (o) CA Large market Recurrence Monitoring Opportunity with 20M women in the U.S. 9 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved. ee WOME

Slide 10: Patient Lifecycle
PATIENT LIFECYCLE e Exdocueck Key Focus Area ENDOMETRIOSIS. Nex . ONLY Inherit JUST ACCEPTED - BENIGN On , DX + Aid in Detection PELVIC MASS HIGH RISK - Current Medical Research MANAGEMENT HEREDITARY Future Opportunity & Opinion Publication - No Surgery Planned OVARIAN CANCER Replace CA125 MONITORIN

Slide 11: Large Benign and Malignant Pelvic Mass Market U.S. Only
LARGE BENIGN AND MALIGNANT PELVIC MASS MARKET U-s. ONLY G Suboptimal diagnostics and high cost burden Large Opportunity Solutions Today Our Solutions Costs Pelvic Masses + (Endo + PCOS+ Fune. Cysts) G NONE - TAM: 17.0M Endo CHECK $22B (2023 Target Date) I Pelvic Masses (Benign, cancer, non-gyn) G CA

Slide 12: Innovation Pipeline Timeline
INNO VaTION PIPELINE TIMELINE Q3 2019 weet 2018 a OF On :;GENETIX Qorus : BY ASPIRA LABS a Hereditary Cancer Carrier Screening 112 Copyright © Aspira Women's Health Inc., 2020. All Rights Reserved. Late 2021 / 1H2022 E 2000F 4 OT ASPIRA GENETIX Qe Teetnstoey rasneret A technology transfer for geneti

Slide 13: Research collaboration announced November 19, 2020
Research collaboration announced November 19, 2020. 13

Slide 14: Starting with Ovarian Cancer
Starting with Ovarian Cancer 114 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserve d.

Slide 15: Presentation Stage and 5-Year Survival Rate
PRESENTATION STAGE AND 5-YEAR SURVIVAL RATE! Presentation Stage Incidence Five Year Survival Rate Stage |) L 15% 9 (Stage I!) Regional 21% 75% Clinical Need for a Diagnostic Solution with Adequate Predictive Value to: + Ensure earlier cancer detection + Accurately identify patients needing timely tr

Slide 16: Root Cause: Inadequate Tools
ROOT CAUSE: INADEQUATE TOOLS Category Tools Physical exam & ultrasound + CA-125 (offabel) + ROMA (ateratve) Pre-operative biopsy not recommended Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved. Limitations Subjective results due to specialists’ interpretation - Low sensitivity + Hi

Slide 17: Current Care Pathway: Majority of Cases Uncertain
CURRENT CARE PATHWAY — MAJORITY OF CASES UNCERTAIN CLEARLY Watchful Waiting / Management of Symptoms Level A guideline | LEVELB for pelvic mass LEVELA - INEFFECTIVE CARE PATHWAY RESULTS GUIDELINE r Rest r 9, assessment results = epee ait @G Late-stage detection (65%)? . Pelvic Mass In ~/0% unclear e

Slide 18: Standalone Risk Stratification
Standalone Risk Stratification CURRENT STATE: EARLY STAGE FALSE NEGATIVE RATE 31-59% A low false negative rate is critical for patient care Early Stage Early Stage False Sensitivity (%) Negativity Rate (%) Clinical assessment (CA)! 68.6 Ultrasound alone? CA125 alone’ ROMA (Ca125 & HE4) 36. Demonstra

Slide 19: Improved Specificity: OVA1 Plus Reflex Offering
IMPROVED SPECIFICITY: OVA1 PLUS - OVA1/OVERA REFLEX OFFERING (Q4 2018) If Results Are... Reported Results are... Intermediate Risk OVA1® v (1) plus > OVA1® Markedly 4106 ovat! Overa? OVA plus % Diff ; (95%CI) (95% cl) (95%Cl) — OVA1 vs OVA1plus Premenopausal? Risk 507.0 H Low INTERMEDIATE ELEVATED S

Slide 20: Improved Early Stage Detection: OVA1 Plus vs. Standard of Care
AIDS IN IMPROVED EARLY STAGE DETECTION: OVA1 PLUS VS. STANDARD OF CARE (STAGE | + II) Rate of Cancer MISSED 94% Improvement in reducing the rate of cancer missed ~ Rate of Cancer DETECTED ‘ 100% (31%) ) 50% hy & & ] - 0% cA-1251" Clinical Modified OVAIPlus OVAiPlus Assessment ‘ACOG™ and Clinical Ass

Slide 21: Disparity Gap Review
Disparity Gap Review NON-WHITE WOMEN, AND AFRICAN-AMERICAN WOMEN IN PARTICULAR, DISPLAY SIGNIFICANTLY LOWER CA125 VALUES COMPARED TO CAUCASIAN WOMEN This disparity is found in healthy women, women at high risk for ovarian cancer, and women with ovarian cancer“) CA125 (%, Caucasian Value is 100%) BAB

Slide 22: OVA1 Superiority Over CA125 in Black Women
Disparity Gap Review OVA1° SUPERIORITY OVER CA125 IN BLACK WOMEN +CA125 has an unacceptable sensitivity for cancer detection in Black women OVA1 vs CA-125 OVA1 vs ROMA + Aug and Sept 2019 BLACK WHITE ary BLACK WHITE - 2 peer reviewed 100 publications published + OVA1® shows acceptable sensitivity fo

Slide 23: Early Detection Lowers Total Healthcare Costs
EARLY DETECTION LOWERS TOTAL HEALTHCARE COSTS Cost Comparison of Early vs. Late Stage Detection’? Pre-Menopausal Late Stage Detection 93K medical claims U $224,922 tinal sanded study demonstrated that : el the use of OVA1 Plus $197,757 compared to CA-125 Il can lower total costs while improving care

Slide 24: A Growing Total Addressable Market
A Growing Total Addressable Market ot ASPIRA WOMEN'S HEALTH 24 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved.

Slide 25: Large and Growing Total Addressable Market
LARGE AND GROWING TOTAL ADDRESSABLE MARKET Currently Addressable Opportunity PELVIC MASS DETECTION + Surgical triage or guided referral: ~300-400K U.S. patients! and low ri + ~5% AWH market share + Current/AWH: OVA1plus HEREDITARY GYNECOLOGIC CANCER RISK + Determining risk for gynecologic cancers wi

Slide 26: Growing Salesforce - Driving Adoption
GROWING SALESFORCE - DRIVING ADOPTION Full-Time Sales Representative Pedigree = AmbryGenetics bostonheart diagnostics? éCareDx Counsyl “ur Prine Transplant Cae Marketed direct! ENOMIND’ r 20 full-time to synecologist, performers 7 . ° ha rmony (“FTE”) gynecology incompanies |f ; territory supergroup

Slide 27: Commercialization Strategy: Decentralized Testing
COMMERCIALIZATION STRATEGY- US + EX US - DECENTRALIZED TESTING ) plus + Testing Performed in Hospital Systems/Large ALGORITHM (\a"’ Gyn Super Group WAREHOUSE + Increase distribution @ POC (Point of Care) 2AGTT CLOUD BASED sre + Test performed locally with access to Aspira BIOINFORMATICS CY. ntciss o

Slide 28: International Commercial Strategy
INTERNATIONAL - COMMERCIAL STRATEGY 28 Copyright © Aspira Women's Health Inc., 2020. All Rights Reserved. Both OVA1/Overa have CE Mark PHILIPPINES Large prospective study in process HI-PRECISION diagnostics ISRAEL Q4 2018 - Coverage received in Israel by CLALIT + 2nd largest integrated delivery netw

Slide 29: Aspira Women's Health Is at a Commercial Inflection Point
ASPIRA WOMEN’S HEALTH IS AT A COMMERCIAL INFLECTION POINT Total Physicians (Distinct Physicians) 3000 2500 2000 1500 1000 500 0 a Q2 Qs Q4 qi Q2 Q3 cr qa Q2 Q3 2018 2019 2020 2020 ©2020 29 Copyright © Aspira Wornen’s Health Inc., 2020. All Rights Reserved.

Slide 30: Aspira Women's Health Is at a Commercial Inflection Point
ASPIRA WOMEN’S HEALTH IS AT A COMMERCIAL INFLECTION POINT Due to COVID-19 Closures PHASE 1 PHASE 2 3,900 HIRING HIRING 3,854 3,700 3,602 3,596 3500 COMMERCIAL . GROWTH PHASE 2.5x commercial S200 investment Y-o-¥ & 3,129 demonstrated positive 3,100 Launch of Decentralized Ob-Gyn reception Platform &

Slide 31: A Review of Financials and Market Access
A Review of Financials and Market Access

Slide 32: Financial and Operating Performance
FINANCIAL AND OPERATING PERFORMANCE it i Reimbi t Grow Base Margin Expansion eimbursemen' gales Markét Share Adoption Capture Revenue and and Leverage Profitability and Revenue Cycle Unit Growth Fixed. Costs Management FY19 VS. FY18 3Q2020 vs 2Q2020 CASH POSITION Product volume Product volume Cash S

Slide 33: Reimbursement and Market Access
REIMBURSEMENT AND MARKET ACCESS Coverage: Patient Lives In Millions O0 G0 BU Montana Oklahoma <7] IGHMARK. GO ov Tennessee NewMexico Arizona HCSC eA Cigna added OVA1 to its Mlinois 120M national preferred coverage list in January 2019 51% of the population now under positive coverage 100M GOAL Targe

Slide 34: Wrap Up and Conclusion
Wrap Up and Conclusion 34 Copyright © Aspira Women’s Health Inc., 2020. Alll Rights Reserved.

Slide 35: Catalyst Driven Momentum Through 2020
CATALYST DRIVEN MOMENTUM THROUGH 2020 {Pama usc EXPANDED MARKET ACCESS VIA CIGNA + Q1 2019: Cigna added OVA1 to its national preferred coverage list MEVICORE GUIDELINES IV PAYER COVERAGE (128M) =15 M lives added (167 M) {EXPANDED SALES TEAM HEREDITARY BREAST AND OVARIAN CANCER + Phase | hiring compl

Slide 36: Enterprise Value: Compelling Growth Strategies
Enterprise Value COMPELLING GROWTH STRATEGIES Expand Product Pipeline; Expand TAM Offer pelvic disease diagnostic and prognostic solutions from puberty to cure from endometriosis and ovarian cancer Become the Standard of Care for Global Pelvic Mass Risk Assessment Leverage the Largest Specimen and D

Slide 37: In Summary
IN SUMMARY Where We Large Market Are Today Opportunity ; Commercial Stage Company a . Solving a Huge with FDA-cleared, Strong pipeline with a Global Healthcare Problem guideline, and payer 20M Market Opportunity ' endorsed technology ra Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserv

Slide 38: Appendix
Appendix j H 38 Copyright © Aspira Women’s Health Inc., 2020. Alll Rights Reserved.

Slide 39: Our Solution: OVA1 + Overa (OVA1 Plus)
OUR SOLUTION = OVA1° + OVERA® (OVA1 PLUS) Ova? + OVA1 evaluates the levels of five ovarian Function C e o nune Horm« cancer-associated markers in the blood Apolipoprotein Beta 2 Protein re mtteeat an CA-12511 Prealbumin Transferrin + Levels combined into single cancer risk score. Multi-variate Index

Slide 40: OVA1 Plus Improves Early Stage Detection
OVA1 PLUS IMPROVES EARLY STAGE DETECTION Comparison of CA-125II vs. OVA1Plus CA-12511 ( Vee” Sensitivity Across All Ovarian Cancer Stages' Stage x (2) Stage Il x () Stage Ill Stage IV Sensitivity Across Menopausal Status’ Pre-menopausal x ~ Post-menopausal Sensitivity Across Histological Subtypes’ E

Slide 41: Trusted Solution: Care Pathway Guidelines
TRUSTED SOLUTION: CARE PATHWAY GUIDELINES Published Evidence Ueland, et al Bristow, et al. Longoria, et al. Goodrich, et al. Forde, et al. Coleman, et al. Eskander, et al. Urban, et al. Brodsky, et al. Shulman, et al. Fredericks, et al. Dunton, et al. Zhang, et al. Dunton, et al. 1.1n 100% of allKey

Slide 42: Protected Solutions: Strong IP
PROTECTED SOLUTIONS: STRONG IP Issued patents covering various Pending patent applications including ovarian cancer OVA1 and Overa biomarkers products GRANTED PENDING (Approx.) USA Ex US. Total USA Ex US. Total 42 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved. 24
Source: Internet Archive copy of aspirawh.com
More decks from Aspira Women's Health Inc.
Investor Presentation (December 2025)35 slides · Dec 31, 2025
Investor Presentation (January 2025)26 slides · Jan 13, 2025
Technical Presentation (October 2024)47 slides · Oct 29, 2024
Investor Day (October 2024)42 slides · Oct 29, 2024
Investor Presentation (September 2024)30 slides · Sep 13, 2024
Fact Sheet (June 2024)2 slides · June 2024